GCA Altium advises CapVest on its acquisition of NextPharma
NextPharma is a market leader in the western European pharmaceutical CDMO space, serving a global blue-chip customer base, including seven of the top ten pharma companies. The company has eight production sites in Europe – five in Germany and one each in Austria, France and Switzerland – with c. 1,000 employees. CapVest acquired NextPharma from an affiliate of Sun Capital Partners, lnc.
CapVest is committed to further enhancing NextPharma’s focus on patient care through the production and supply of the highest quality medicines from its state-of-the-art European production facilities.
Christopher Campbell, Partner at CapVest, stated: “NextPharma is an excellent business with a leadership position in a growing market and we look forward to supporting management on the next exciting phase in the company’s journey.”
GCA Altium presented various financing scenarios to CapVest, involving both senior banks and debt funds. “We are convinced that CapVest is the ideal partner for the management team of NextPharma. The chosen financing structure gives the company the flexibility needed in combination with very attractive terms,” commented Norbert Schmitz, Managing Director at GCA Altium.